Wound monitoring

• US 20050079542A1
• Filed: 11/05/2002
• Published: 04/14/2005
• Est. Priority Date: 11/05/2001
• Status: Active Grant

• Current Assignee: Woundcheck Laboratories (US), Inc., Woundchek Laboratories (US), Inc.
• Original Assignee: Systagenix Wound Management Ip Co., B.V (3M Company), Systagenix Wound Management (US), Inc.
• Inventors: Cullen, Breda Mary
• Granted Patent: US 7,794,925 B2
• Time in Patent Office: Days
• US Class Current: 435/7.100
• CPC Class Codes: C12Q 1/37 involving peptidase or proteinase
• CPC Class Codes: G01N 2333/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: G01N 33/573 for enzymes or isoenzymes
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

A method of predicting or diagnosing clinical infection of a wound comprising measuring the concentration of a maker associated with an inflammatory response in wound fluid, wherein the maker is a fibronectin fragment, a neutrophil protease or a macrophage protease. Also provided is a use of a wound dressing or biosensor comprising components of an assay system for measuring the concentration of a marker associated with an inflammatory response, wherein the marker is a fibronectin fragment, a neutrophil protease or a macrophage protease, for use in the manufacture of a medicament for predicting the likelihood of clinical infection of the wound or for diagnosing clinical infection of a wound.

Claims

1. A method of predicting or diagnosing clinical infection of a wound comprising measuring the concentration of a marker associated with an inflammatory response in wound fluid, wherein the marker is a fibronectin fragment, a neutrophil protease or a macrophage protease.

3. The method of claim 1 wherein the marker is neutrophil elastase.

4. The method or use according to claim 1 wherein the wound is a chronic wound.

5. The method or use according to claim 4 wherein the chronic wound is a chronic ulcer such as a dermal ulcer, venous ulcer, pressure sore or decubitis ulcer.

6. The method or use according to claim 1 wherein the concentration of the marker is measured using an immunological, spectrophotometric, colorimetric, fluorimetric, or radioactive detection based technique.

7. The method or use according to claim 1 wherein the concentration of the marker is measured by a dip-stick type test.

2. (canceled)